Other OTC - Delayed Quote USD

Alzex Neuropharma Inc. (TRRI)

0.2470 +0.0970 (+64.67%)
At close: April 26 at 3:57 PM EDT
Key Events
Loading Chart for TRRI
DELL
  • Previous Close 0.1500
  • Open 0.2370
  • Bid --
  • Ask --
  • Day's Range 0.1700 - 0.2470
  • 52 Week Range 0.1020 - 0.5000
  • Volume 3,892
  • Avg. Volume 463
  • Market Cap (intraday) 371,801
  • Beta (5Y Monthly) -36.35
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Alzex Neuropharma Inc., a development stage biopharmaceutical company, engages in developing therapeutics for the treatment of Alzheimer's Disease and other neurological diseases. The company was formerly known as Trinity Resources Inc. and changed its name to Alzex Neuropharma Inc. in December 2022. The company was incorporated in 1971 and is headquartered in Las Vegas, Nevada.

www.trinresinc.com

--

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: TRRI

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TRRI
23.50%
S&P 500
6.92%

1-Year Return

TRRI
13.33%
S&P 500
25.26%

3-Year Return

TRRI
262.17%
S&P 500
22.00%

5-Year Return

TRRI
1,876.00%
S&P 500
74.29%

Compare To: TRRI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TRRI

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    371.80k

  • Enterprise Value

    371.80k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.68%

  • Return on Assets (ttm)

    -1.64%

  • Return on Equity (ttm)

    2.85%

  • Revenue (ttm)

    4.73M

  • Net Income Avi to Common (ttm)

    32.05k

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    63.5k

  • Total Debt/Equity (mrq)

    76.40%

  • Levered Free Cash Flow (ttm)

    198.14k

Company Insights: TRRI

People Also Watch